---
schema_version: "secwatch.filing_event.v1"
accession: "0001000694-25-000031"
form_type: "8-K"
ticker: "NVAX"
cik: "0001000694"
company_name: "NOVAVAX INC"
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T18:48:01.750313+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Novavax Q2 revenue $239M; net income $107M; $175M Sanofi milestone from FDA BLA approval

## Summary
- Total revenue of $239M, down 42% YoY, includes $175M milestone from Nuvaxovid BLA approval.
- Net income of $107M vs $162M YoY; cash $628M; $175M milestone receipt expected Q3 2025.
- Updated FY2025 adjusted total revenue guidance to $1,000-1,050M (prior $975-1,025M).
- Combined R&D/SG&A expense guidance raised to $495-545M; includes $20M postmarketing study cost.
- Phase 3 data for COVID-flu combo and standalone flu candidates showed robust immune responses.

## SEC filing metadata
- accession: 0001000694-25-000031
- form_type: 8-K
- ticker: NVAX
- cik: 0001000694
- company_name: NOVAVAX INC
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1000694/000100069425000031/0001000694-25-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1000694/000100069425000031/nvax-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001000694-25-000031
- JSON: https://secwatch.observer/filing/0001000694-25-000031.json
- Plain text: https://secwatch.observer/filing/0001000694-25-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.